Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AKR1B1P2 is a processed pseudogene and a retrocopy of the functional gene AKR1B1, which encodes a member of the aldo-keto reductase enzyme superfamily involved in NADPH-dependent oxidoreduction reactions[1][7][9]. Pseudogenes like AKR1B1P2 are typically noncoding and considered biologically inert; however, recent research into analogous pseudogenes (such as AKR1B10P1 and PTENP1) suggests a minority may exert regulatory functions in cancer by acting as molecular sponges for miRNAs, potentially modulating gene expression of their parental genes and influencing tumorigenesis via ceRNA mechanisms[2][6]. There is currently no direct evidence of AKR1B1P2 playing a functional role in disease or drug response.
Not applicable—no functional protein product, therefore no classic mechanism of action for drug targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aldo-keto reductase family 1 member B1 pseudogene 2 (AKR1B1P2).